May 8 |
InflaRx GAAP EPS of -€0.17 beats by €0.07, revenue of €36.03M beats by €35.89M
|
May 8 |
InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update
|
May 7 |
InflaRx Q1 2024 Earnings Preview
|
Apr 30 |
InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024
|
Apr 24 |
InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
|
Mar 21 |
InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates
|
Mar 21 |
InflaRx reports FY results
|
Mar 21 |
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
|
Mar 19 |
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
|
Mar 6 |
Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?
|